Publications - Page 21 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Mycobactéries non tuberculeuses (MNT)
International Pediatric Otolaryngology Group: Consensus guidelines on the diagnosis and management of non-tuberculous mycobacterial cervicofacial lymphadenitis.

Roy CF, Balakrishnan K, Boudewyns A, Cheng A, Chun RH, Daniel SJ, Fayoux P, Hart C, Hemansson A, Hewitt R, Hsu WC, Kuo M, Liu C, Maddalozzo J, Messner AH, Pransky S, Rahbar R, Rickert S, Roy S, Russell J, Rutter MJ, Sie KCY, Sidell D, Smith R, Soma M, Spratley J, Watters K, White DR, Wolter N, Zalzal G, Yeung JC.

Int J Pediatr Otorhinolaryngol. 2023 Mar;166:111469.
Dilatation des bronches ou bronchectasies (non CF, non DCP)
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC).

Chalmers JD, Polverino E, Crichton ML, Ringshausen FC, De Soyza A, Vendrell M, Burgel PR, Haworth CS, Loebinger MR, Dimakou K, Murris M, Wilson R, Hill AT, Menendez R, Torres A, Welte T, Blasi F, Altenburg J, Shteinberg M, Boersma W, Elborn JS, Goeminne PC, Aliberti S; EMBARC Registry Investigators.

Lancet Respir Med. 2023 Jul;11(7):637-649.
Mycobactéries non tuberculeuses (MNT)
Towards clinical breakpoints for non-tuberculous mycobacteria – Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.

Fröberg G, Maurer FP, Chryssanthou E, Fernström L, Benmansour H, Boarbi S, Mengshoel AT, Keller PM, Viveiros M, Machado D, Fitzgibbon MM, Mok S, Werngren J, Cirillo DM, Alcaide F, Hyyryläinen HL, Aubry A, Andres S, Nadarajan D, Svensson E, Turnidge J, Giske CG, Kahlmeter G, Cambau E, van Ingen J, Schön T; EUCAST AMST and ESCMYC study groups.

Clin Microbiol Infect. 2023 Jun;29(6):758-764.
Mycobactéries non tuberculeuses (MNT)
Epidemiology of infection by pulmonary non-tuberculous mycobacteria in French Guiana 2008-2018.

Chaptal M, Andrejak C, Bonifay T, Beillard E, Guillot G, Guyomard-Rabenirina S, Demar M, Trombert-Paolantoni S, Jacomo V, Mosnier E, Veziris N, Djossou F, Epelboin L; French Guiana PNTM working group.

PLoS Negl Trop Dis. 2022 Sep 9;16(9):e0010693.
Dyskinésies ciliaires primitives (DCP)
Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.

Shoemark A, Griffin H, Wheway G, Hogg C, Lucas JS; Genomics England Research Consortium; Camps C, Taylor J, Carroll M, Loebinger MR, Chalmers JD, Morris-Rosendahl D, Mitchison HM, De Soyza A; Genomics England Research Consortium:; Brown D, Ambrose JC, Arumugam P, Bevers R, Bleda M, Boardman-Pretty F, Boustred CR, Brittain H, Caulfield MJ, Chan GC, Fowler T, Giess A, Hamblin A, Henderson S, Hubbard TJP, Jackson R, Jones LJ, Kasperaviciute D, Kayikci M, Kousathanas A, Lahnstein L, Leigh SEA, Leong IUS, Lopez FJ, Maleady-Crowe F, McEntagart M, Minneci F, Moutsianas L, Mueller M, Murugaesu N, Need AC, O'Donovan P, Odhams CA, Patch C, Perez-Gil D, Pereira MB, Pullinger J, Rahim T, Rendon A, Rogers T, Savage K, Sawant K, Scott RH, Siddiq A, Sieghart A, Smith SC, Sosinsky A, Stuckey A, Tanguy M, Taylor Tavares AL, Thomas ERA, Thompson SR, Tucci A, Welland MJ, Williams E, Witkowska K, Wood SM.

Eur Respir J. 2022 Nov 17;60(5):2200176.
Fibrose pulmonaire - FPI
Autoantibodies are associated with disease progression in idiopathic pulmonary fibrosis.

Koether K, Besnard V, Sandig H, Carruthers A, Miranda E, Grootenboer-Mignot S, Taillé C, Chevret S, Valeyre D, Nunes H, Israel-Biet D, Lim WK, Cottin V, Corkill D, Dobson C, Groves M, Ferraro F, Guenzi E, Huang L, Sulikowski M, Mailleux A, Murray LA, Mustelin T, Strickland I, Sleeman MA, Crestani B.

Eur Respir J. 2023 May 18;61(5):2102381.
Fibrose pulmonaire - FPI
A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Podolanczuk AJ, Cottin V.

Adv Ther. 2023 May;40(5):2038-2050.
Dilatation des bronches ou bronchectasies (non CF, non DCP)
Alpha1-antitrypsin deficiency: An updated review.

Mornex JF, Traclet J, Guillaud O, Dechomet M, Lombard C, Ruiz M, Revel D, Reix P, Cottin V.

Presse Med. 2023 Jul 28:104170.
Pneumopathies interstitielles diffuses (PID)
Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.

Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P, Borie R, Brillet PY, Cadranel J, Court-Fortune I, Crestani B, Debray MP, Gomez E, Gondouin A, Hirschi-Santelmo S, Israel-Biet D, Jouneau S, Juvin K, Leger J, Kerjouan M, Marquette CH, Naccache JM, Nunes H, Plantier L, Prevot G, Quetant S, Traclet J, Valentin V, Uzunhan Y, Wémeau-Stervinou L, Bejan-Angoulvant T, Cottin V, Marchand-Adam S; EVER-ILD investigators and the OrphaLung network.

Eur Respir J. 2023 Jun 8;61(6):2202071.
Dilatation des bronches ou bronchectasies (non CF, non DCP)
Bronchiolitis obliterans syndrome following SARS-CoV-2 infection in an allogeneic hematopoietic stem cell recipient.

Bondeelle L, Giannotti F, Chalandon Y, Le Goff J, Tapparel C, Bergeron A.

Am J Transplant. 2023 Jun;23(6):844-847.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

International Pediatric Otolaryngology Group: Consensus guidelines on the diagnosis and management of non-tuberculous mycobacterial cervicofacial lymphadenitis.

Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC).

Towards clinical breakpoints for non-tuberculous mycobacteria – Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.

Epidemiology of infection by pulmonary non-tuberculous mycobacteria in French Guiana 2008-2018.

Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.

Autoantibodies are associated with disease progression in idiopathic pulmonary fibrosis.

A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Alpha1-antitrypsin deficiency: An updated review.

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.

Bronchiolitis obliterans syndrome following SARS-CoV-2 infection in an allogeneic hematopoietic stem cell recipient.